Skip to main content
Explore URMC

menu

A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma

Research Question:
What is the efficacy and safety of chemotherapy drug, brentuximab vedotin, in front-line therapy of Hodgkin Lymphoma in adults age 60 and above?

Basic Study Information

Purpose:
This is an open-label clinical trial designed to evaluate the effectiveness and safety of brentuximab vedotin, a chemotherapy drug, as front-line therapy of Hodgkin Lymphoma in adults age 60 and above. It will be given as a single treatment (Part A) or in combination with dacarbazine (Part B), or in combination with bendamustine (Part C), or in combination with nivolumab (Part D).

Study Reference #: ILYM12066

Lead Researcher (Principal Investigator)

Lead Researcher: Jonathan Friedberg, MD

Study Contact Information

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search